La Jolla Pharma (LJPC) 23.04 $LJPC La Jolla

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 9:30 PM

La Jolla Pharma (LJPC) 23.04 $LJPC

La Jolla Pharmaceutical (LJPC) in Focus: Stock Up 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:46AM CDT
La Jolla Pharmaceutical (LJPC) was a big mover last session, with shares rising over 14% on the day.
LJPC: 23.04 (+1.22), ARQL: 2.11 (-0.03)

La Jolla Pharmaceutical Company Announces Additions to LJPC-401 Advisory Board
Business Wire - Wed Apr 22, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the addition of four new members to its advisory board for the development of LJPC-401, La Jolla's novel formulation of hepcidin. The advisory board is composed of internationally renowned clinicians, highly respected academics and key opinion leaders in the fields of gastroenterology, hematology and oncology. The new members of the advisory board are Paul Adams, M.D., Victor Gordeuk, M.D., Ashutosh Lal, M.D., and Gordon McLaren, M.D.
LJPC: 23.04 (+1.22)

Nasdaq stocks posting largest percentage increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TTS: 14.52 (-0.33), FATE: 6.29 (-0.10), HAS: 71.73 (-1.82), ADXS: 22.18 (+0.10), AMSC: 10.40 (+1.20), ECHO: 33.39 (+1.37), LJPC: 23.04 (+1.22), RMBS: 14.40 (+0.22), TGLS: 11.98 (+0.70), VLTC: 15.14 (-1.04), FTNT: 38.07 (-0.01)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 11:47AM CDT

RNO: 1.95 (-0.12), ECHO: 33.39 (+1.37), LJPC: 23.04 (+1.22), CEA: 45.82 (-0.73), NVGN: 7.40 (-0.30), NHLD: 3.80 (-0.20), VLTC: 15.14 (-1.04), GEVO: 2.78 (+0.77), BIOD: 1.24 (-0.01), PRTO: 12.15 (-0.08), TTS: 14.52 (-0.33), ENZN: 1.70 (+0.20), AST: 13.61 (-0.11), VGGL: 2.77 (+0.27), GLF: 13.77 (-0.11), NVTA: 12.76 (-1.12), FTK: 15.56 (+0.10), PGN: 1.82 (+0.06), UCTT: 5.66 (+0.14), SANM: 21.09 (+0.40)

5 Stocks Ready for Breakouts
at The Street - Fri Apr 17, 8:09AM CDT
These stocks look poised to break out and trade higher from current levels.
ANY: 3.33 (-0.16), LJPC: 23.04 (+1.22), PHMD: 1.96 (+0.02), TRAK: 39.49 (+0.33), AAPL: 128.62 (+1.71)

New finance chief at La Jolla Pharma
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 9:04AM CDT

LJPC: 23.04 (+1.22)

La Jolla Pharmaceutical Company Appoints Dennis Mulroy as Chief Financial Officer
Business Wire - Mon Apr 06, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that Dennis Mulroy will join the Company as Chief Financial Officer, effective today.
LJPC: 23.04 (+1.22)

Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups
James Sands - at Seeking Alpha - Tue Mar 31, 8:40PM CDT

PCYC: 256.98 (-0.77), FB: 84.63 (+1.01), LJPC: 23.04 (+1.22), SAFM: 78.03 (-0.62), ICE: 225.61 (+1.49), ILMN: 190.04 (-9.27), HP: 73.53 (+1.48), PCLN: 1,212.90 (+18.64), WWAV: 45.54 (-0.56), SQNM: 4.47 (+0.08), ACAD: 38.55 (-0.20), HALO: 16.03 (+0.15), GILD: 104.18 (-1.02), TRN: 32.82 (-3.43), QCOM: 68.94 (+0.37), FFIV: 120.42 (+1.49), MBLY: 47.47 (+0.93), UNP: 110.73 (+1.23), MA: 91.20 (+3.43), IPGP: 97.60 (+1.46)

La Jolla Pharmaceuticals: A Busy 2015 Ahead
Robert K. Stuart - at Seeking Alpha - Tue Mar 24, 11:53AM CDT

LJPC: 23.04 (+1.22), ICPT: 280.45 (-8.26)

La Jolla Pharma initiates late stage LJPC-501 trial
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 8:50AM CDT

LJPC: 23.04 (+1.22)

La Jolla Pharmaceutical Company Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension
Business Wire - Tue Mar 24, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated its ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial, a Phase 3 clinical trial of LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). In February 2015, La Jolla reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA), in which it was agreed that the primary efficacy endpoint for the trial would be increase in blood pressure. CRH is an acute, life-threatening condition in which blood pressure drops to dangerously low levels in patients who respond poorly to current treatments.
LJPC: 23.04 (+1.22)

La Jolla Pharma starts Phase 2 kidney disease study
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:57AM CDT

LJPC: 23.04 (+1.22)

La Jolla Pharmaceutical Company Announces Initiation of Phase 2b Clinical Trial of GCS-100 in Advanced Chronic Kidney Disease
Business Wire - Wed Mar 18, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated its Phase 2b clinical trial of GCS-100 for the treatment of advanced chronic kidney disease (CKD) caused by diabetes. CKD is a condition characterized by a gradual loss of kidney function over time that may eventually lead to kidney failure, requiring dialysis or a kidney transplant to maintain life.
LJPC: 23.04 (+1.22)

La Jolla Pharmaceutical posts 4Q loss
Automated Insights - Mon Mar 16, 5:58PM CDT
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Monday reported a loss of $6.8 million in its fourth quarter.
LJPC: 23.04 (+1.22)

La Jolla Pharmaceutical misses by $0.08
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 4:16PM CDT

LJPC: 23.04 (+1.22)

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Highlights
Business Wire - Mon Mar 16, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported fourth quarter and full year 2014 financial results and highlighted recent corporate progress and near-term milestones.
LJPC: 23.04 (+1.22)

Differences in NASH studies make direct comparisons a bit tricky
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 9:56AM CDT

GLMD: 10.00 (-0.12), RPTP: 10.56 (-0.17), GILD: 104.18 (-1.02), LJPC: 23.04 (+1.22), CNAT: 6.31 (-0.15), SHPG: 253.58 (+3.70), MRK: 57.69 (+0.03), GALT: 3.29 (+0.01), ICPT: 280.45 (-8.26), RGDO: 1.23 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BeyondCPG Accelerator Launches Seventh Growth Program

Fresh Faces in Conscious Consumerism There's nothing quite like an early morning jolt of caffeine mixed with the buzz of innovation in the air. BeyondCPG, a heavyweight in the conscious products arena, has cracked open the doors to its seventh round of powerhouse brand-boosting with the launch of its new Accelerator Track 7. They're mixing heart with hustle to give...

Apex Dental's Growth Shines in Inc. 5000 Ranking

Another Year, Another Milestone for Apex Dental Let's talk about steady growth. Apex Dental Partners has made it onto the Inc. 5000 list for the eighth straight year, landing at No. 3,850. Quite a feat, considering this list only features America's fastest-growing private companies. Apex isn't just maintaining its position out of sheer luck. Revenue shot up by 67% over...

Stravito's MCP Server Revolutionizes AI in Business

We're seeing another big swing in how enterprises weave AI into the fabric of decision-making. Stravito, an enterprise customer intelligence platform, launched its Model Context Protocol (MCP) Server. This thing brings company-owned research right into the gizmos teams already use. Now, businesses aren't left groping in the dark figuring out their next moves—pretty...

Kansas City Current's Grand Playoff Push in 2026

A Celebration of Fans and Momentum Some things are bigger than just a match. The Kansas City Current’s event, 'One Current 2026: Bigger Home. Bigger Future.' ain't just another day on the pitch. This is about expanding a vision that has the whole town buzzing. On Sunday, October 25, the buzzhits fever pitch as CPKC Stadium rolls out the biggest event in its...

Newmark's $482.5M Loan Fuels Steamboat Resort Expansion

Newmark Banks on Steamboat's Future Diving headfirst into the deep end, Newmark (NASDAQ: NMRK) just roped in a colossal $482.5 million loan for a new gem in Steamboat Springs, Colorado. Inking a deal of this magnitude ain't your everyday rinse-and-repeat; it's a bold move that speaks volumes about where the big shots think value's heading. The Financial Fuel: GoldenTree...

Decision Logic Innovates with Vitals & ShiftFlow Tools

Restaurant Battlefields: The Need for Real-Time Response Running a restaurant is no walk in the park. One slip, and you're dealing with spoiled soup or crabby customers. Decision Logic reckons they've cracked the code to smoother operations with their new tools, Vitals and ShiftFlow. At heart, these products do one thing: put critical data into the hands of managers while...

Youth Mental Health: New Survey Spurs Action

What's the 2025 Survey Telling Us? Numbers hit like a gut punch, don't they? The 2025 National Youth Risk Behavior Survey unveils some hard truths — truths that can't be softer just because we've made headway. We're talking about one in three high schoolers in this country feeling persistently down. That's about 33.3% of them, wrestling with sadness and hopelessness...

VERTESS Tops Axial's 2026 Healthcare M&A Advisor List

Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...

Navigating Hit and Run Protocols in St. Tammany Parish

When the Driver Disappears: Steps Forward Hit and run accidents can leave you feeling abandoned and unsure of what to do. In St. Tammany Parish, this scenario is all too familiar. Personal Injury Attorney Ross F. Lagarde cuts through the chaos, offering a clear path for those caught in this nightmare, explained in HelloNation's comprehensive guide. Prioritize Safety and...

Seatrium, Karpowership Wrap Landmark FSRU Partnership

A Milestone in Global Energy Infrastructure Out of Admiralty Yard in Singapore comes a transformation saga that’s begging for attention. Seatrium Limited and Karpowership have pulled off something spectacular with their seventh and final Floating Storage and Regasification Unit (FSRU), LNGT Türkiye. It's not just another vessel hitting the waters—it's the bookend on...